⌘K
E
Epicrispr Biotechnologies
Healthcare & Life Sciences
Recent Finacing
Series B
Recent Raise
$68M
Epicrispr Biotechnologies specializes in developing gene-modulating therapies, focusing on treatments for facioscapulohumeral muscular dystrophy (FSHD) using their proprietary Gene Expression Modulation System (GEMS).
Focus Areas
Gene-modulating
therapies
facioscapulohumeral muscular dystrophy
clinical development
proprietary technology
first-in-human trial
Investors
